Literature DB >> 31955212

Expression of podoplanin correlates with prognosis in nasopharyngeal carcinoma.

Philipp Wolber1, David Schwarz2, Maximilian Niemczyk2, Uta Drebber3, Jens Peter Klußmann2, Moritz Meyer2.   

Abstract

PURPOSE: Podoplanin is a membrane-bound glycoprotein that plays a role in lymphangiogenesis. Several studies suggest a role of podoplanin in head-and-neck cancer. The purpose of the current study was to evaluate the role of podoplanin as a prognostic marker in nasopharyngeal carcinoma.
METHODS: In a monocentric retrospective analysis, data of 42 patients with primary diagnosis of nasopharyngeal carcinoma (diagnosed between 2004 and 2017) were examined regarding the relationship between the immunohistochemically analyzed podoplanin expression status and corresponding clinical and oncological parameters.
RESULTS: The mean age was 56.6 years. The majority (61.9%) had an advanced tumor stage (T3-T4). The 5-year overall survival was 54%. 33% showed a positive expression of podoplanin. In patients with tumors with podoplanin expression, 5-year overall survival was 15%, while in patients with tumors without podoplanin expression, 5-year overall survival was 75% (p = 0.017, univariate analysis). In multivariate analysis, podoplanin expression was shown to be the only independent prognostic marker for nasopharyngeal carcinoma (p = 0.025).
CONCLUSION: This retrospective study shows that podoplanin expression is a potential prognostic marker for nasopharyngeal carcinomas. In the future, clinical use could filter out more aggressive courses and allow therapy escalation in those cases.

Entities:  

Keywords:  Biomarkers; Immunohistochemistry; Nasopharyngeal carcinoma; Prognosis

Mesh:

Substances:

Year:  2020        PMID: 31955212     DOI: 10.1007/s00405-020-05785-3

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  31 in total

Review 1.  New insights into the role of podoplanin in epithelial-mesenchymal transition.

Authors:  Jaime Renart; Patricia Carrasco-Ramírez; Beatriz Fernández-Muñoz; Ester Martín-Villar; Lucía Montero; María M Yurrita; Miguel Quintanilla
Journal:  Int Rev Cell Mol Biol       Date:  2015-03-05       Impact factor: 6.813

2.  Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition.

Authors:  Ester Martín-Villar; Diego Megías; Susanna Castel; Maria Marta Yurrita; Senén Vilaró; Miguel Quintanilla
Journal:  J Cell Sci       Date:  2006-10-17       Impact factor: 5.285

3.  Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin.

Authors:  Leah N Cueni; Ivan Hegyi; Jay W Shin; Andrea Albinger-Hegyi; Silke Gruber; Rainer Kunstfeld; Holger Moch; Michael Detmar
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

4.  Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.

Authors:  K C Allen Chan; John K S Woo; Ann King; Benny C Y Zee; W K Jacky Lam; Stephen L Chan; Sam W I Chu; Constance Mak; Irene O L Tse; Samantha Y M Leung; Gloria Chan; Edwin P Hui; Brigette B Y Ma; Rossa W K Chiu; Sing-Fai Leung; Andrew C van Hasselt; Anthony T C Chan; Y M Dennis Lo
Journal:  N Engl J Med       Date:  2017-08-10       Impact factor: 91.245

5.  Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431.

Authors:  Naho Atsumi; Genichiro Ishii; Motohiro Kojima; Masaru Sanada; Satoshi Fujii; Atsushi Ochiai
Journal:  Biochem Biophys Res Commun       Date:  2008-06-06       Impact factor: 3.575

6.  Podoplanin is expressed at the invasive front of esophageal squamous cell carcinomas and is involved in collective cell invasion.

Authors:  Yuichiro Nakashima; Keiji Yoshinaga; Hiroyuki Kitao; Koji Ando; Yasue Kimura; Hiroshi Saeki; Eiji Oki; Masaru Morita; Yoshihiro Kakeji; Minako Hirahashi; Yoshinao Oda; Yoshihiko Maehara
Journal:  Cancer Sci       Date:  2013-10-22       Impact factor: 6.716

7.  Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia.

Authors:  Davide Bartolomeo Gissi; Andrea Gabusi; Achille Tarsitano; Laura Luccarini; Luca Morandi; Lucio Montebugnoli
Journal:  J Craniomaxillofac Surg       Date:  2018-03-09       Impact factor: 2.078

8.  Concordant podoplanin expression in cancer-associated fibroblasts and tumor cells is an adverse prognostic factor in esophageal squamous cell carcinoma.

Authors:  Wen-Yu Chuang; Chi-Ju Yeh; Yin-Kai Chao; Yun-Hen Liu; Yu-Sun Chang; Chen-Kan Tseng; Hsien-Kun Chang; Yung-Liang Wan; Chuen Hsueh
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

9.  Expression of podoplanin and prognosis in oropharyngeal cancer.

Authors:  Simon F Preuss; Andreas Anagiotos; Inga M C Seuthe; Uta Drebber; Inga Wedemeyer; Matthias Kreppel; Robert Semrau; Guy D Eslick; Jens Peter Klussmann; Christian U Huebbers
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-01       Impact factor: 2.503

Review 10.  The potential role of podoplanin in tumour invasion.

Authors:  A Wicki; G Christofori
Journal:  Br J Cancer       Date:  2006-12-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.